{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-22-000096","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.716060+00:00","generated_at":"2026-06-24T02:31:07.403105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22","bullets":["Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.","GAAP net income $70.7M ($0.22 diluted EPS) vs $96.1M ($0.30) in Q2 2021; non-GAAP EPS $0.28.","Cash and investments $2.0B at June 30, 2022, up from $1.9B at year-end 2021.","Positive PFS data for COSMIC-313; initiated STELLAR-303 phase 3 for XL092 and phase 1 for XL114.","Signed business development agreements with BioInvent and Ryvu Therapeutics to expand biologics capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-22-000096","json":"https://secwatch.observer/filing/0000939767-22-000096.json","markdown":"https://secwatch.observer/filing/0000939767-22-000096.md","text":"https://secwatch.observer/filing/0000939767-22-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/0000939767-22-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/exel-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:31:07.403105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}